10700177	81	Kaplan JM	Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis.	Nature genetics	2000	264
10699153	183	Kim S	Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases.	Pharmacological reviews	2000	150
12511528	183	Kobori H	Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension.	Hypertension	2003	96
15149345	183	de Zeeuw D	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.	Kidney international	2004	141
15919782	183	Wolf G	From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy.	Diabetes	2005	124
16336578	183	Remuzzi G	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.	Kidney international. Supplement	2005	68
17409317	183	Eijkelkamp WB	Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.	Journal of the American Society of Nephrology 	2007	57
19075095	183	Kobori H	Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients.	Hypertension	2009	60
19145003	183	Parving HH	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.	Nephrology, dialysis, transplantation 	2009	51
19240212	183	San-Cristobal P	Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway.	Proceedings of the National Academy of Sciences of the United States of America	2009	90
20181807	183	Workeneh BT	Review of muscle wasting associated with chronic kidney disease.	The American journal of clinical nutrition	2010	47
20234356	183	Briet M	Aldosterone: effects on the kidney and cardiovascular system.	Nature reviews. Nephrology	2010	50
20351344	183	Forman JP	Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans.	Hypertension	2010	53
20442753	183	Kotsis V	Mechanisms of obesity-induced hypertension.	Hypertension research 	2010	67
22922412	183	McCurley A	Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors.	Nature medicine	2012	63
23022011	183	Khan SR	Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations.	The Journal of urology	2013	31
24144355	183	Schiffrin EL	Immune mechanisms in hypertension and vascular injury.	Clinical science	2014	39
24981816	183	Wang XH	Mechanisms of muscle wasting in chronic kidney disease.	Nature reviews. Nephrology	2014	28
25092601	183	Alge JL	Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications.	Clinical journal of the American Society of Nephrology 	2015	23
25767285	183	Hall JE	Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.	Circulation research	2015	52
15703421	185	Dragun D	Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.	The New England journal of medicine	2005	111
25003615	185	Chaiworapongsa T	Pre-eclampsia part 1: current understanding of its pathophysiology.	Nature reviews. Nephrology	2014	61
15375022	197	Moe SM	Pathophysiology of vascular calcification in chronic kidney disease.	Circulation research	2004	79
15504939	197	Reynolds JL	Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD.	Journal of the American Society of Nephrology 	2004	140
17021608	197	Zhou H	Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury.	Kidney international	2006	73
20664518	197	Sage AP	Regulatory mechanisms in vascular calcification.	Nature reviews. Cardiology	2010	87
25711438	197	Kapustin AN	Vascular smooth muscle cell calcification is mediated by regulated exosome secretion.	Circulation research	2015	36
26908770	197	Brandenburg VM	Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry.	Nephrology, dialysis, transplantation 	2017	7
10910062	207	Sekulić A	A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.	Cancer research	2000	166
14612533	207	Christensen JG	A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.	Cancer research	2003	133
15800227	207	Stallone G	Sirolimus for Kaposi's sarcoma in renal-transplant recipients.	The New England journal of medicine	2005	140
17018841	207	Lee MJ	A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy.	American journal of physiology. Renal physiology	2007	83
19796751	207	Rini BI	Resistance to targeted therapy in renal-cell carcinoma.	The Lancet. Oncology	2009	126
20049901	207	Morigi M	Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury.	Stem cells	2010	47
21385509	207	Brasnyó P	Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.	The British journal of nutrition	2011	104
21779001	207	Kato H	mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway.	Cell death and differentiation	2012	60
22891270	207	Armstrong AJ	Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.	Journal of clinical oncology 	2012	36
24242861	207	Rosenberg JE	A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.	Investigational new drugs	2014	32
24467442	207	Hawley SA	Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells.	The Biochemical journal	2014	26
25012178	207	Wang H	GIV/girdin links vascular endothelial growth factor signaling to Akt survival signaling in podocytes independent of nephrin.	Journal of the American Society of Nephrology 	2015	18
26947078	207	Chen F	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.	Cell reports	2016	24
8731095	213	Witko-Sarsat V	Advanced oxidation protein products as a novel marker of oxidative stress in uremia.	Kidney international	1996	160
11961019	213	Paniagua R	Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.	Journal of the American Society of Nephrology 	2002	91
15625072	213	Muntner P	Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study.	Journal of the American Society of Nephrology 	2005	90
15660573	213	Don BR	Serum albumin: relationship to inflammation and nutrition.	Seminars in dialysis	2004	82
18514987	213	Tentori F	Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).	American journal of kidney diseases 	2008	150
19171851	213	Kalantar-Zadeh K	Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis.	Circulation	2009	91
20075063	213	Friedman AN	Reassessment of albumin as a nutritional marker in kidney disease.	Journal of the American Society of Nephrology 	2010	50
21601335	213	Mehrotra R	Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with hemodialysis.	American journal of kidney diseases 	2011	38
23467560	213	Berg AH	Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure.	Science translational medicine	2013	25
24025647	213	Hung SC	Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease.	Kidney international	2014	29
22842478	335	Walter S	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.	Nature medicine	2012	217
27431356	335	O'Donnell MJ	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.	Lancet	2016	28
16627561	354	Groskopf J	APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.	Clinical chemistry	2006	76
17382159	354	Marks LS	PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.	Urology	2007	67
17785564	354	Hessels D	Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.	Clinical cancer research 	2007	77
18245462	354	Laxman B	A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.	Cancer research	2008	103
18295257	354	Deras IL	PCA3: a molecular urine assay for predicting prostate biopsy outcome.	The Journal of urology	2008	68
18824702	354	Tolcher AW	Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.	Journal of clinical oncology 	2008	59
19409690	354	Tomlins SA	ETS gene fusions in prostate cancer: from discovery to daily clinical practice.	European urology	2009	98
19636023	354	Stephenson AJ	Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.	Journal of clinical oncology 	2009	79
20117878	354	Jentzmik F	Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours.	European urology	2010	44
22099611	354	Armstrong AJ	Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.	European urology	2012	43
22998901	354	Crawford ED	Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases.	The Journal of urology	2012	31
24177197	354	Dijkstra S	Clinical use of novel urine and blood based prostate cancer biomarkers: a review.	Clinical biochemistry	2014	25
24836057	354	Klein EA	A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.	European urology	2014	68
25385735	354	Wei JT	Can urinary PCA3 supplement PSA in the early detection of prostate cancer?	Journal of clinical oncology 	2014	36
25466945	354	Klein EA	A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.	European urology	2015	28
25613154	354	Gratzke C	EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.	European urology	2015	34
25964175	354	Tomlins SA	Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.	European urology	2015	20
26790878	354	Saini S	PSA and beyond: alternative prostate cancer biomarkers.	Cellular oncology	2016	10
26992225	354	Koppers-Lalic D	Non‑invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles.	Oncotarget	2016	11
27032035	354	McKiernan J	A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.	JAMA oncology	2016	16
8140421	359	Deen PM	Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine.	Science	1994	131
15326289	359	Pisitkun T	Identification and proteomic profiling of exosomes in human urine.	Proceedings of the National Academy of Sciences of the United States of America	2004	403
20686450	359	Rood IM	Comparison of three methods for isolation of urinary microvesicles to identify biomarkers of nephrotic syndrome.	Kidney international	2010	47
16303870	551	Wismer Fries AB	Early experience in humans is associated with changes in neuropeptides critical for regulating social behavior.	Proceedings of the National Academy of Sciences of the United States of America	2005	96
23227301	551	Staruschenko A	Regulation of transport in the connecting tubule and cortical collecting duct.	Comprehensive Physiology	2012	33
23121377	554	Torres VE	Tolvaptan in patients with autosomal dominant polycystic kidney disease.	The New England journal of medicine	2012	174
9362426	567	Coleman RE	Skeletal complications of malignancy.	Cancer	1997	204
12371953	567	Himmelfarb J	The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia.	Kidney international	2002	182
12490682	567	Eknoyan G	Effect of dialysis dose and membrane flux in maintenance hemodialysis.	The New England journal of medicine	2002	199
12528874	567	Kyle RA	Review of 1027 patients with newly diagnosed multiple myeloma.	Mayo Clinic proceedings	2003	255
15809451	567	Greipp PR	International staging system for multiple myeloma.	Journal of clinical oncology 	2005	339
11120762	632	Falahati-Nini A	Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men.	The Journal of clinical investigation	2000	116
25930984	712	Tambur AR	Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information.	American journal of transplantation 	2015	20
26047793	712	Guidicelli G	Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.	Journal of the American Society of Nephrology 	2016	13
11431351	920	Nakano O	Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.	Cancer research	2001	107
12411292	920	Gamadia LE	Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.	Blood	2003	108
15327410	920	Szczech LA	The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.	Kidney international	2004	80
16796719	920	Fudaba Y	Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses.	American journal of transplantation 	2006	67
17135583	920	Strategies for Management of Antiretroviral Therapy (SMART) Study Group.	CD4+ count-guided interruption of antiretroviral treatment.	The New England journal of medicine	2006	629
17457094	920	Szczech LA	Microalbuminuria in HIV infection.	AIDS	2007	58
18427202	920	Baker JV	CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.	AIDS	2008	106
19838127	920	Horberg M	Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.	Journal of acquired immune deficiency syndromes	2010	41
20086230	920	Vendrame F	Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells.	Diabetes	2010	62
20108382	920	Lawn SD	Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease.	AIDS	2009	81
20181972	920	Cain KP	An algorithm for tuberculosis screening and diagnosis in people with HIV.	The New England journal of medicine	2010	87
20352098	920	Dheda K	Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples.	PloS one	2010	47
21063582	920	Zhu H	Cost-effective and compact wide-field fluorescent imaging on a cell-phone.	Lab on a chip	2011	62
21725250	920	Byrd DA	Neurocognitive impact of substance use in HIV infection.	Journal of acquired immune deficiency syndromes	2011	46
22362849	920	Peter JG	Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients.	The European respiratory journal	2012	53
22824630	920	Kalayjian RC	Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.	AIDS	2012	36
23886064	920	Lederman MM	Residual immune dysregulation syndrome in treated HIV infection.	Advances in immunology	2013	68
24497929	920	Serrano-Villar S	Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio.	PloS one	2014	32
24602844	920	Grinsztejn B	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.	The Lancet. Infectious diseases	2014	101
24675585	920	Nakiyingi L	Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults.	Journal of acquired immune deficiency syndromes	2014	31
25036865	920	Rosado MM	Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells.	Stem cells and development	2015	15
7574193	966	Peterson JC	Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.	Annals of internal medicine	1995	129
9669788	966	Pérez-Stable EJ	Nicotine metabolism and intake in black and white smokers.	JAMA	1998	162
12570944	966	Manjunath G	Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.	Journal of the American College of Cardiology	2003	107
15781736	966	Sackner-Bernstein JD	Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.	Circulation	2005	92
16253727	966	Gelber RP	Association between body mass index and CKD in apparently healthy men.	American journal of kidney diseases 	2005	73
16408129	966	Eriksen BO	The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age.	Kidney international	2006	82
17267695	966	Sadowski EA	Nephrogenic systemic fibrosis: risk factors and incidence estimation.	Radiology	2007	105
17309916	966	Briguori C	Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.	Circulation	2007	59
18295053	966	Zhang L	Prevalence and factors associated with CKD: a population study from Beijing.	American journal of kidney diseases 	2008	55
18337481	966	Weiner DE	Uric acid and incident kidney disease in the community.	Journal of the American Society of Nephrology 	2008	75
18585836	966	Kurella Tamura M	Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.	American journal of kidney diseases 	2008	98
19218538	966	Schiffmann R	Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.	Nephrology, dialysis, transplantation 	2009	57
19303683	966	Madero M	Uric acid and long-term outcomes in CKD.	American journal of kidney diseases 	2009	65
19332353	966	Krum H	Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.	Lancet	2009	258
19339091	966	White SL	Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies.	American journal of kidney diseases 	2009	59
19358576	966	Tycko R	Evidence for novel beta-sheet structures in Iowa mutant beta-amyloid fibrils.	Biochemistry	2009	53
19394734	966	Shah SN	Serum bicarbonate levels and the progression of kidney disease: a cohort study.	American journal of kidney diseases 	2009	50
19559169	966	Wilhelm-Leen ER	Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey.	The American journal of medicine	2009	64
20100732	966	Závada J	A comparison of three methods to estimate baseline creatinine for RIFLE classification.	Nephrology, dialysis, transplantation 	2010	42
20124537	966	Hemmelgarn BR	Relation between kidney function, proteinuria, and adverse outcomes.	JAMA	2010	201
20138414	966	White SL	Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study.	American journal of kidney diseases 	2010	56
20170948	966	Bakris GL	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.	Lancet	2010	50
20172445	966	Stevens LA	Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP).	American journal of kidney diseases 	2010	56
20207457	966	Crews DC	Poverty, race, and CKD in a racially and socioeconomically diverse urban population.	American journal of kidney diseases 	2010	45
20332400	966	Hemmelgarn BR	Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate.	JAMA	2010	51
20385436	966	Bellomo G	Association of uric acid with change in kidney function in healthy normotensive individuals.	American journal of kidney diseases 	2010	42
20415897	966	Vincenti F	A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).	American journal of transplantation 	2010	149
20441712	966	Black C	Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.	Health technology assessment	2010	43
20557989	966	Stevens LA	Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2.	American journal of kidney diseases 	2010	105
20884698	966	Di Angelantonio E	Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study.	BMJ	2010	44
21059968	966	Rosansky SJ	Early start of hemodialysis may be harmful.	Archives of internal medicine	2011	41
21098347	966	Roussel R	Metformin use and mortality among patients with diabetes and atherothrombosis.	Archives of internal medicine	2010	47
21403038	966	de Boer IH	Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.	Archives of internal medicine	2011	64
21482743	966	Tangri N	A predictive model for progression of chronic kidney disease to kidney failure.	JAMA	2011	136
21693741	966	de Boer IH	Temporal trends in the prevalence of diabetic kidney disease in the United States.	JAMA	2011	163
21992533	966	Vincenti F	Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.	American journal of transplantation 	2012	47
22028277	966	Zoppini G	Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.	Diabetes care	2012	33
22194591	966	Udy AA	Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.	Chest	2012	44
22206742	966	Jotwani V	Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors.	American journal of kidney diseases 	2012	31
22206744	966	Mammen C	Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: a prospective cohort study.	American journal of kidney diseases 	2012	52
22337679	966	Thadhani R	Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.	JAMA	2012	90
22733312	966	Bao Y	Frailty, dialysis initiation, and mortality in end-stage renal disease.	Archives of internal medicine	2012	57
22770927	966	Roshanravan B	A prospective study of frailty in nephrology-referred patients with CKD.	American journal of kidney diseases 	2012	46
22889713	966	Kilbride HS	Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly.	American journal of kidney diseases 	2013	30
22936784	966	Alexander RT	Kidney stones and kidney function loss: a cohort study.	BMJ	2012	37
23022429	966	Wong CJ	CKiD (CKD in children) prospective cohort study: a review of current findings.	American journal of kidney diseases 	2012	30
23111824	966	Hallan SI	Age and association of kidney measures with mortality and end-stage renal disease.	JAMA	2012	95
23360717	966	Nitsch D	Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis.	BMJ	2013	44
23489677	966	Dobre M	Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.	American journal of kidney diseases 	2013	33
23714169	966	Singh AK	Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study.	BMC nephrology	2013	30
24042021	966	Bose B	Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.	Nephrology, dialysis, transplantation 	2014	32
24047110	966	Rostaing L	Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.	American journal of transplantation 	2013	32
24067879	966	Gane EJ	Telbivudine improves renal function in patients with chronic hepatitis B.	Gastroenterology	2014	27
24092942	966	Blood Pressure Lowering Treatment Trialists' Collaboration.	Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.	BMJ	2013	29
24182662	966	Yang W	Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.	American journal of kidney diseases 	2014	24
24902920	966	Ambrosius WT	The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).	Clinical trials	2014	47
25393378	966	Naik RP	Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.	JAMA	2014	23
25529816	966	Molnar MZ	Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.	Hepatology	2015	20
25531343	966	Mugwanya KK	Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.	JAMA internal medicine	2015	18
25562264	966	Livingstone SJ	Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010.	JAMA	2015	32
25795794	966	Germain DP	Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.	Journal of medical genetics	2015	20
26038534	966	Molnar MZ	Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans.	Thorax	2015	17
26162677	966	Hoste EA	Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study.	Intensive care medicine	2015	75
26337133	966	Grams ME	Acute Kidney Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data.	American journal of kidney diseases 	2016	19
26857595	966	Chang Y	Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study.	Annals of internal medicine	2016	16
26867814	966	Obi Y	Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study.	American journal of kidney diseases 	2016	13
26906014	966	Billings FT 4th	High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.	JAMA	2016	21
7543698	1080	Stutts MJ	CFTR as a cAMP-dependent regulator of sodium channels.	Science	1995	200
15105504	1080	Egan ME	Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects.	Science	2004	97
21083385	1080	Accurso FJ	Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.	The New England journal of medicine	2010	180
21262823	1080	Takiar V	Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	47
2492638	1161	Fischer G	Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins.	Nature	1989	225
15590763	1351	Foley RN	Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.	Journal of the American Society of Nephrology 	2005	165
16820797	1351	Kalantar-Zadeh K	Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.	Kidney international	2006	178
19012918	1351	Huang WC	Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes?	The Journal of urology	2009	108
19131355	1351	Wizemann V	The mortality risk of overhydration in haemodialysis patients.	Nephrology, dialysis, transplantation 	2009	86
22223429	1351	Kovesdy CP	Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure.	Circulation	2012	38
23802192	1351	Robinson BM	Worldwide, mortality risk is high soon after initiation of hemodialysis.	Kidney international	2014	21
26384521	1351	Kovesdy CP	Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans.	Circulation	2015	22
10200738	1392	Baker DG	Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder.	The American journal of psychiatry	1999	96
10867111	1392	Zobel AW	Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.	Journal of psychiatric research	2000	97
11238541	1392	Rask E	Tissue-specific dysregulation of cortisol metabolism in human obesity.	The Journal of clinical endocrinology and metabolism	2001	94
11430844	1392	Heim C	The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies.	Biological psychiatry	2001	456
18334580	1392	Nieman LK	The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.	The Journal of clinical endocrinology and metabolism	2008	148
24153250	1392	Vanuytsel T	Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism.	Gut	2014	26
9987089	1401	Zimmermann J	Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.	Kidney international	1999	125
10231453	1401	Stenvinkel P	Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.	Kidney international	1999	158
11728958	1401	Kalantar-Zadeh K	A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients.	American journal of kidney diseases 	2001	96
11916939	1401	Stehouwer CD	Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death.	Diabetes	2002	94
12515748	1401	Shlipak MG	Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency.	Circulation	2003	125
14581334	1401	Trikha M	Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.	Clinical cancer research 	2003	102
14871421	1401	Oberg BP	Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease.	Kidney international	2004	127
15086475	1401	Simmons EM	Plasma cytokine levels predict mortality in patients with acute renal failure.	Kidney international	2004	83
15262830	1401	Selvin E	Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.	Circulation	2004	263
15827312	1401	Shlipak MG	Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors.	JAMA	2005	152
15941879	1401	Noakes M	Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women.	The American journal of clinical nutrition	2005	66
16251239	1401	Fried LF	Kidney function as a predictor of noncardiovascular mortality.	Journal of the American Society of Nephrology 	2005	78
16267155	1401	Shlipak MG	Cystatin C and mortality risk in the elderly: the health, aging, and body composition study.	Journal of the American Society of Nephrology 	2006	66
16377395	1401	Honda H	Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.	American journal of kidney diseases 	2006	72
17182988	1401	Wang TJ	Multiple biomarkers for the prediction of first major cardiovascular events and death.	The New England journal of medicine	2006	238
17470699	1401	Ford ES	Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents.	Circulation	2007	90
17502528	1401	Dhingra R	Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.	Archives of internal medicine	2007	171
17701281	1401	Kanbay M	Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions.	International urology and nephrology	2007	71
17910386	1401	Haack M	Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers.	Sleep	2007	114
18256376	1401	Szeto CC	Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients.	Clinical journal of the American Society of Nephrology 	2008	52
18385206	1401	Astor BC	Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population.	American journal of epidemiology	2008	72
18843258	1401	Ravani P	Vitamin D levels and patient outcome in chronic kidney disease.	Kidney international	2009	85
19070949	1401	Rambod M	Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study.	American journal of kidney diseases 	2009	53
19088165	1401	Pittas AG	Association between serum osteocalcin and markers of metabolic phenotype.	The Journal of clinical endocrinology and metabolism	2009	88
19406957	1401	Zaritsky J	Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.	Clinical journal of the American Society of Nephrology 	2009	53
19443637	1401	de Boer IH	25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification.	Journal of the American Society of Nephrology 	2009	69
20016471	1401	Barreto DV	Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease.	Kidney international	2010	51
20181810	1401	Bakker GC	An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach.	The American journal of clinical nutrition	2010	42
20203163	1401	Matias PJ	Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.	Clinical journal of the American Society of Nephrology 	2010	43
20397003	1401	Mårtensson J	Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury.	Intensive care medicine	2010	62
20538833	1401	Goicoechea M	Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.	Clinical journal of the American Society of Nephrology 	2010	124
20569726	1401	Soliman EZ	Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC).	American heart journal	2010	46
20605303	1401	Shafi T	Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.	American journal of kidney diseases 	2010	42
20643463	1401	Ohno Y	Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma.	The Journal of urology	2010	47
20682604	1401	Upadhyay A	Inflammation, kidney function and albuminuria in the Framingham Offspring cohort.	Nephrology, dialysis, transplantation 	2011	38
20876676	1401	Yu M	Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress.	Clinical journal of the American Society of Nephrology 	2011	41
21257787	1401	Allen RW	An air filter intervention study of endothelial function among healthy adults in a woodsmoke-impacted community.	American journal of respiratory and critical care medicine	2011	38
21866089	1401	Shankar A	Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study.	Kidney international	2011	40
22431676	1401	Kavousi M	Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study.	Annals of internal medicine	2012	57
22658574	1401	Anderson AH	Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study.	American journal of kidney diseases 	2012	63
22735432	1401	Ebbeling CB	Effects of dietary composition on energy expenditure during weight-loss maintenance.	JAMA	2012	59
23141484	1401	Yamamoto S	Dysfunctional high-density lipoprotein in patients on chronic hemodialysis.	Journal of the American College of Cardiology	2012	37
23454726	1401	Waldron JL	Vitamin D: a negative acute phase reactant.	Journal of clinical pathology	2013	29
24429405	1401	Sinha A	Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.	Kidney international	2014	21
24819981	1401	Semba RD	Resveratrol levels and all-cause mortality in older community-dwelling adults.	JAMA internal medicine	2014	22
25054777	1401	Freedman BI	APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes.	Kidney international	2015	26
25683387	1401	Al Rifai M	The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA).	Atherosclerosis	2015	20
26271406	1401	Hunt L	Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study.	The Lancet. Infectious diseases	2015	32
26494833	1401	Besarab A	Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.	Journal of the American Society of Nephrology 	2016	13
15256590	1432	Huffman DL	Mitogen-activated protein kinase pathways defend against bacterial pore-forming toxins.	Proceedings of the National Academy of Sciences of the United States of America	2004	113
16452201	1432	Zetser A	Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation.	Cancer research	2006	80
17392283	1432	Medvedev AE	Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance.	The Journal of biological chemistry	2007	61
19236889	1432	Siu ER	Cadmium-induced testicular injury.	Toxicology and applied pharmacology	2009	54
19654295	1432	Yodkeeree S	Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species.	Cancer research	2009	45
22969168	1432	Lim AK	Inflammation in diabetic nephropathy.	Mediators of inflammation	2012	62
15327406	1471	Herget-Rosenthal S	Early detection of acute renal failure by serum cystatin C.	Kidney international	2004	155
15607309	1471	Filler G	Cystatin C as a marker of GFR--history, indications, and future research.	Clinical biochemistry	2005	111
15809461	1471	Sarnak MJ	Cystatin C concentration as a risk factor for heart failure in older adults.	Annals of internal medicine	2005	94
15901858	1471	Shlipak MG	Cystatin C and the risk of death and cardiovascular events among elderly persons.	The New England journal of medicine	2005	289
15961546	1471	Grubb A	Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children.	Clinical chemistry	2005	72
16408133	1471	Rule AD	Glomerular filtration rate estimated by cystatin C among different clinical presentations.	Kidney international	2006	72
16697315	1471	Smith GL	Renal impairment and outcomes in heart failure: systematic review and meta-analysis.	Journal of the American College of Cardiology	2006	109
16908914	1471	Shlipak MG	Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.	Annals of internal medicine	2006	141
17190862	1471	Ix JH	Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.	Circulation	2007	74
17329575	1471	Perkins BA	Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes.	Journal of the American Society of Nephrology 	2007	105
17464129	1471	Devarajan P	Emerging biomarkers of acute kidney injury.	Contributions to nephrology	2007	58
17699320	1471	Furth SL	Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study.	Clinical journal of the American Society of Nephrology 	2006	104
18094679	1471	Coca SG	Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review.	Kidney international	2008	141
18235143	1471	Baxmann AC	Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C.	Clinical journal of the American Society of Nephrology 	2008	74
18295055	1471	Stevens LA	Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.	American journal of kidney diseases 	2008	337
18650797	1471	Koyner JL	Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery.	Kidney international	2008	75
19001197	1471	Rifkin DE	Rapid kidney function decline and mortality risk in older adults.	Archives of internal medicine	2008	99
19114878	1471	Haase-Fielitz A	Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery--a prospective cohort study.	Critical care medicine	2009	71
19119287	1471	Stevens LA	Factors other than glomerular filtration rate affect serum cystatin C levels.	Kidney international	2009	113
19158356	1471	Schwartz GJ	New equations to estimate GFR in children with CKD.	Journal of the American Society of Nephrology 	2009	343
19820136	1471	Schwartz GJ	Measurement and estimation of GFR in children and adolescents.	Clinical journal of the American Society of Nephrology 	2009	71
20332356	1471	Ficociello LH	High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.	Diabetes care	2010	43
20445497	1471	Mahajan A	Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.	Kidney international	2010	56
20446848	1471	Neuhaus J	Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.	The Journal of infectious diseases	2010	225
20709438	1471	Choi A	Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons.	American journal of kidney diseases 	2010	43
20798258	1471	Koyner JL	Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury.	Clinical journal of the American Society of Nephrology 	2010	87
21307838	1471	Endre ZH	Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function.	Kidney international	2011	64
21482744	1471	Peralta CA	Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality.	JAMA	2011	97
21601330	1471	Zhang Z	Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis.	American journal of kidney diseases 	2011	43
22095948	1471	Ralib AM	Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury.	Journal of the American Society of Nephrology 	2012	34
22240130	1471	Nickolas TL	Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study.	Journal of the American College of Cardiology	2012	66
22305758	1471	Astor BC	Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population.	American journal of kidney diseases 	2012	48
22418979	1471	Nejat M	Some biomarkers of acute kidney injury are increased in pre-renal acute injury.	Kidney international	2012	38
22622496	1471	Schwartz GJ	Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C.	Kidney international	2012	49
22626821	1471	Duranton F	Normal and pathologic concentrations of uremic toxins.	Journal of the American Society of Nephrology 	2012	84
22733462	1471	Mahfoud F	Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension.	Hypertension	2012	39
22762315	1471	Inker LA	Estimating glomerular filtration rate from serum creatinine and cystatin C.	The New England journal of medicine	2012	450
23024164	1471	Gupta J	Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC.	Clinical journal of the American Society of Nephrology 	2012	47
23027318	1471	Schaeffner ES	Two novel equations to estimate kidney function in persons aged 70 years or older.	Annals of internal medicine	2012	68
23273292	1471	Metra M	Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.	Journal of the American College of Cardiology	2013	58
23393104	1471	Goraya N	A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate.	Clinical journal of the American Society of Nephrology 	2013	40
23423253	1471	Rule AD	Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease.	Kidney international	2013	30
23619125	1471	Grams ME	Trends in the prevalence of reduced GFR in the United States: a comparison of creatinine- and cystatin C-based estimates.	American journal of kidney diseases 	2013	28
24004120	1471	Shlipak MG	Cystatin C versus creatinine in determining risk based on kidney function.	The New England journal of medicine	2013	122
24247300	1471	Chen HH	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.	JAMA	2013	54
24485147	1471	Levey AS	GFR estimation: from physiology to public health.	American journal of kidney diseases 	2014	37
24694986	1471	Goraya N	Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate.	Kidney international	2014	22
25195004	1471	Wasung ME	Biomarkers of renal function, which and when?	Clinica chimica acta; international journal of clinical chemistry	2015	24
25554404	1471	Raman SV	Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.	The Lancet. Neurology	2015	26
25599331	1471	Tang WH	Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.	Circulation research	2015	78
10485724	1490	Ko AI	Urban epidemic of severe leptospirosis in Brazil. Salvador Leptospirosis Study Group.	Lancet	1999	195
20393144	1490	Wang B	E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta.	Diabetes	2010	81
20522536	1490	Adler SG	Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.	Clinical journal of the American Society of Nephrology 	2010	45
16039586	1499	Ding Q	Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.	Molecular cell	2005	175
18632682	1499	Lal M	Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling.	Human molecular genetics	2008	62
19060336	1499	Yu J	A Wnt7b-dependent pathway regulates the orientation of epithelial cell division and establishes the cortico-medullary axis of the mammalian kidney.	Development	2009	83
19718039	1499	Lancaster MA	Impaired Wnt-beta-catenin signaling disrupts adult renal homeostasis and leads to cystic kidney ciliopathy.	Nature medicine	2009	66
22095947	1499	He W	Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/β-catenin activity in CKD.	Journal of the American Society of Nephrology 	2012	40
22115830	1499	Freeman TJ	Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin.	Gastroenterology	2012	39
25600645	1499	Hirata H	Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205.	Cancer research	2015	81
26364599	1499	Zhou L	Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.	Oncogene	2016	25
16176115	1544	Anderson GD	Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.	Clinical pharmacokinetics	2005	130
23132334	1544	Reese MJ	In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.	Drug metabolism and disposition	2013	35
16581329	1576	Law M	Statin safety: a systematic review.	The American journal of cardiology	2006	97
17097610	1576	Suetsugu A	Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells.	Biochemical and biophysical research communications	2006	141
18288078	1576	Hebert MF	Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study.	Clinical pharmacology and therapeutics	2008	52
19514965	1576	Klotz U	Pharmacokinetics and drug metabolism in the elderly.	Drug metabolism reviews	2009	45
19581388	1576	Pan YZ	MicroRNAs regulate CYP3A4 expression via direct and indirect targeting.	Drug metabolism and disposition	2009	58
20170205	1576	Staatz CE	Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.	Clinical pharmacokinetics	2010	44
21903774	1576	Elens L	A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.	Clinical chemistry	2011	41
22015057	1576	Garcia-Donas J	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.	The Lancet. Oncology	2011	60
24249597	1576	Hesselink DA	The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.	Clinical pharmacokinetics	2014	24
20393454	1577	Thervet E	Optimization of initial tacrolimus dose using pharmacogenetic testing.	Clinical pharmacology and therapeutics	2010	48
20530282	1577	McLeod HL	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.	Journal of clinical oncology 	2010	46
17889607	1628	Heudorf U	Phthalates: toxicology and exposure.	International journal of hygiene and environmental health	2007	99
1463530	1636	SOLVD Investigators.	Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.	The New England journal of medicine	1992	239
8413456	1636	Lewis EJ	The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.	The New England journal of medicine	1993	490
8596594	1636	Maschio G	Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.	The New England journal of medicine	1996	125
9217756	1636	-	Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)	Lancet	1997	153
10924499	1636	Tipnis SR	A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase.	The Journal of biological chemistry	2000	198
10969042	1636	Donoghue M	A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.	Circulation research	2000	242
11181474	1636	Guerin AP	Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure.	Circulation	2001	116
11260414	1636	Kambham N	Obesity-related glomerulopathy: an emerging epidemic.	Kidney international	2001	156
11386927	1636	Agodoa LY	Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.	JAMA	2001	110
11453706	1636	Jafar TH	Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.	Annals of internal medicine	2001	100
11566918	1636	London GM	Arterial wave reflections and survival in end-stage renal failure.	Hypertension	2001	109
12531578	1636	Nakao N	Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.	Lancet	2003	78
12788992	1636	Perkins BA	Regression of microalbuminuria in type 1 diabetes.	The New England journal of medicine	2003	147
12965979	1636	Jafar TH	Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.	Annals of internal medicine	2003	133
13678870	1636	Granger CB	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.	Lancet	2003	137
14769700	1636	McAlister FA	Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study.	Circulation	2004	92
15766995	1636	Ruggenenti P	Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.	Lancet	2005	83
16338452	1636	Casas JP	Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.	Lancet	2005	78
17035613	1636	Rüster C	Renin-angiotensin-aldosterone system and progression of renal disease.	Journal of the American Society of Nephrology 	2006	67
17984482	1636	Kunz R	Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.	Annals of internal medicine	2008	94
17984484	1636	Matchar DB	Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.	Annals of internal medicine	2008	63
18707986	1636	Mann JF	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.	Lancet	2008	243
19846849	1636	ESCAPE Trial Group.	Strict blood-pressure control and progression of renal failure in children.	The New England journal of medicine	2009	100
19926893	1636	Mehdi UF	Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.	Journal of the American Society of Nephrology 	2009	69
20440277	1636	Ruggenenti P	The RAAS in the pathogenesis and treatment of diabetic nephropathy.	Nature reviews. Nephrology	2010	43
21705121	1636	Fischer MJ	CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies.	American journal of kidney diseases 	2011	46
21791491	1636	Slagman MC	Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.	BMJ	2011	41
22135311	1636	Vegter S	Sodium intake, ACE inhibition, and progression to ESRD.	Journal of the American Society of Nephrology 	2012	42
22166847	1636	Gross O	Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.	Kidney international	2012	35
23100218	1636	Ruggenenti P	Mechanisms and treatment of CKD.	Journal of the American Society of Nephrology 	2012	34
24206457	1636	Fried LF	Combined angiotensin inhibition for the treatment of diabetic nephropathy.	The New England journal of medicine	2013	107
25399731	1636	Torres VE	Angiotensin blockade in late autosomal dominant polycystic kidney disease.	The New England journal of medicine	2014	25
26009228	1636	Palmer SC	Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.	Lancet	2015	30
16380482	1803	Segal MS	Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes.	Diabetes	2006	67
21672124	1803	Graefe-Mody U	Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*).	Diabetes, obesity and metabolism	2011	39
23033241	1803	McGill JB	Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.	Diabetes care	2013	35
23932846	1803	Aroor AR	Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.	Metabolism	2013	41
24225429	1803	Fujita H	DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.	Endocrine journal	2014	22
24732974	1803	DeMarco VG	The pathophysiology of hypertension in patients with obesity.	Nature reviews. Endocrinology	2014	43
14990351	1906	Gladwin MT	The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation.	Free radical biology and medicine	2004	73
17065335	1906	Schmid H	Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy.	Diabetes	2006	104
15782206	1956	Chen I	Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase.	Nature methods	2005	155
17082756	1956	Chonchol M	25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey.	Kidney international	2007	63
18761338	1956	Zeng F	The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology.	Experimental cell research	2009	48
19429932	1956	Mirza MA	Relationship between circulating FGF23 and total body atherosclerosis in the community.	Nephrology, dialysis, transplantation 	2009	51
20189275	1956	Matsushita K	Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study.	American journal of kidney diseases 	2010	64
20416999	1956	Horio M	Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates.	American journal of kidney diseases 	2010	52
21107446	1956	Stevens LA	Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities.	Kidney international	2011	45
21338849	1956	Stevens LA	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP).	American journal of kidney diseases 	2011	38
21355053	1956	Rosolowsky ET	Risk for ESRD in type 1 diabetes remains high despite renoprotection.	Journal of the American Society of Nephrology 	2011	52
21646496	1956	Alonso A	Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.	Circulation	2011	73
21852664	1956	Thomas G	Metabolic syndrome and kidney disease: a systematic review and meta-analysis.	Clinical journal of the American Society of Nephrology 	2011	89
21881553	1956	Goraya N	Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy.	Kidney international	2012	40
23045285	1956	Gusenbauer S	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.	Oncogene	2013	35
23275377	1956	Bansal N	Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease.	Circulation	2013	29
23687356	1956	Rhee EP	A combined epidemiologic and metabolomic approach improves CKD prediction.	Journal of the American Society of Nephrology 	2013	40
24429397	1956	Niewczas MA	Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.	Kidney international	2014	27
24652789	1956	Lu JL	Association of body mass index with outcomes in patients with CKD.	Journal of the American Society of Nephrology 	2014	33
24722445	1956	de Zeeuw D	The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.	Journal of the American Society of Nephrology 	2014	36
24904092	1956	Irazabal MV	Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.	Journal of the American Society of Nephrology 	2015	24
24970885	1956	Navarro-González JF	Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.	Journal of the American Society of Nephrology 	2015	18
25556173	1956	Loupy A	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.	Journal of the American Society of Nephrology 	2015	20
25573908	1956	Kopp JB	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.	Journal of the American Society of Nephrology 	2015	22
25589610	1956	Schanstra JP	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.	Journal of the American Society of Nephrology 	2015	21
25677388	1956	Banerjee T	High Dietary Acid Load Predicts ESRD among Adults with CKD.	Journal of the American Society of Nephrology 	2015	17
26040904	1956	Solé C	miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis.	Nephrology, dialysis, transplantation 	2015	21
26229137	1956	Stubbs JR	Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.	Journal of the American Society of Nephrology 	2016	27
26912543	1956	Torres VE	Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.	Clinical journal of the American Society of Nephrology 	2016	10
27383068	1956	Hill NR	Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.	PloS one	2016	21
27745820	1956	Langer CJ	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.	The Lancet. Oncology	2016	29
2062846	2056	Semenza GL	Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene.	Proceedings of the National Academy of Sciences of the United States of America	1991	144
9718377	2056	Besarab A	The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.	The New England journal of medicine	1998	260
11844847	2056	Casadevall N	Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.	The New England journal of medicine	2002	103
14525788	2056	Bahlmann FH	Erythropoietin regulates endothelial progenitor cells.	Blood	2004	76
15284297	2056	Sharples EJ	Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion.	Journal of the American Society of Nephrology 	2004	81
17108342	2056	Drüeke TB	Normalization of hemoglobin level in patients with chronic kidney disease and anemia.	The New England journal of medicine	2006	290
17108343	2056	Singh AK	Correction of anemia with epoetin alfa in chronic kidney disease.	The New England journal of medicine	2006	385
17276778	2056	Phrommintikul A	Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.	Lancet	2007	80
17488680	2056	Origa R	Liver iron concentrations and urinary hepcidin in beta-thalassemia.	Haematologica	2007	81
17656472	2056	Foley RN	End-stage renal disease in the United States: an update from the United States Renal Data System.	Journal of the American Society of Nephrology 	2007	88
18324962	2056	Arcasoy MO	The non-haematopoietic biological effects of erythropoietin.	British journal of haematology	2008	78
18458324	2056	Tong Z	Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications.	Proceedings of the National Academy of Sciences of the United States of America	2008	53
19212416	2056	Ashby DR	Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease.	Kidney international	2009	50
19834012	2056	Ehrenreich H	Recombinant human erythropoietin in the treatment of acute ischemic stroke.	Stroke	2009	145
20164823	2056	Endre ZH	Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial).	Kidney international	2010	67
21115615	2056	Bernhardt WM	Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.	Journal of the American Society of Nephrology 	2010	65
23291219	2056	Haase VH	Regulation of erythropoiesis by hypoxia-inducible factors.	Blood reviews	2013	57
23457296	2056	Bunn HF	Erythropoietin.	Cold Spring Harbor perspectives in medicine	2013	33
24645943	2056	Kamar N	Ribavirin for chronic hepatitis E virus infection in transplant recipients.	The New England journal of medicine	2014	44
25535770	2056	Salvagno GL	Red blood cell distribution width: A simple parameter with multiple clinical applications.	Critical reviews in clinical laboratory sciences	2015	34
26976799	2056	Pockros PJ	Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.	Gastroenterology	2016	18
17059688	2078	Laxman B	Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.	Neoplasia	2006	62
19212411	2078	Sreekumar A	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.	Nature	2009	492
21813756	2078	Tomlins SA	Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.	Science translational medicine	2011	98
23201468	2078	Leyten GH	Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.	European urology	2014	56
10962009	2147	Lee SL	Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.	The Journal of biological chemistry	2000	93
17506785	2147	Stangier J	The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.	British journal of clinical pharmacology	2007	104
18006647	2147	Blech S	The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.	Drug metabolism and disposition	2008	82
20214409	2147	Stangier J	Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.	Clinical pharmacokinetics	2010	91
21972820	2147	Liesenfeld KH	Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.	Journal of thrombosis and haemostasis 	2011	36
22037947	2147	Davalos D	Fibrinogen as a key regulator of inflammation in disease.	Seminars in immunopathology	2012	83
23991661	2147	Eikelboom JW	Dabigatran versus warfarin in patients with mechanical heart valves.	The New England journal of medicine	2013	75
26855967	2147	In J	Enterohemorrhagic &lt;i&gt;Escherichia coli&lt;/i&gt; reduce mucus and intermicrovillar bridges in human stem cell-derived colonoids.	Cellular and molecular gastroenterology and hepatology	2016	14
18094680	2168	Portilla D	Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery.	Kidney international	2008	80
22093507	2168	Krawczeski CD	Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass.	Journal of the American College of Cardiology	2011	51
23599408	2168	Parikh CR	Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery.	Clinical journal of the American Society of Nephrology 	2013	43
23689653	2168	McCullough PA	Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference.	Contributions to nephrology	2013	33
24005224	2168	Arthur JM	Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery.	Kidney international	2014	25
24375576	2168	Belcher JM	Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury.	Hepatology	2014	30
25316431	2168	Fufaa GD	Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus.	Diabetologia	2015	16
25882434	2168	Basu RK	Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology in critically ill children (AWARE): study protocol for a prospective observational study.	BMC nephrology	2015	15
10862640	2244	Guérin AP	Arterial stiffening and vascular calcifications in end-stage renal disease.	Nephrology, dialysis, transplantation 	2000	95
22144540	2244	Zhang YZ	Hemorrhagic fever caused by a novel Bunyavirus in China: pathogenesis and correlates of fatal outcome.	Clinical infectious diseases 	2012	52
11865300	2271	Tomlinson IP	Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.	Nature genetics	2002	253
12772087	2271	Toro JR	Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.	American journal of human genetics	2003	93
14634372	2271	Linehan WM	The genetic basis of cancer of the kidney.	The Journal of urology	2003	94
18728283	2271	Ricketts C	Germline SDHB mutations and familial renal cell carcinoma.	Journal of the National Cancer Institute	2008	82
19963135	2271	Yang Y	UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.	Cancer genetics and cytogenetics	2010	42
21907923	2271	Tong WH	The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.	Cancer cell	2011	51
23747014	2271	Sullivan LB	The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling.	Molecular cell	2013	57
27580029	2271	Sciacovelli M	Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.	Nature	2016	22
7680480	2335	Yamamoto T	Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy.	Proceedings of the National Academy of Sciences of the United States of America	1993	133
8127021	2335	Ryan MJ	HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney.	Kidney international	1994	155
12815434	2335	Sakai T	Fibronectin requirement in branching morphogenesis.	Nature	2003	150
15938030	2335	Schena FP	Pathogenetic mechanisms of diabetic nephropathy.	Journal of the American Society of Nephrology 	2005	76
16436674	2335	McDaniel SM	Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis.	The American journal of pathology	2006	65
22169009	2335	Sanchez-Niño MD	Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.	American journal of physiology. Renal physiology	2012	37
15899889	2475	Chiang GG	Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase.	The Journal of biological chemistry	2005	152
16341243	2475	Thomas GV	Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.	Nature medicine	2006	163
17253963	2475	Findlay GM	A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling.	The Biochemical journal	2007	96
17360704	2475	Roux PP	RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation.	The Journal of biological chemistry	2007	202
17595159	2475	Chan EY	siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy.	The Journal of biological chemistry	2007	134
18184959	2475	Bissler JJ	Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.	The New England journal of medicine	2008	278
18460336	2475	Gulati P	Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34.	Cell metabolism	2008	120
18614546	2475	Rosner M	Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.	Human molecular genetics	2008	71
18653228	2475	Motzer RJ	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.	Lancet	2008	647
18722871	2475	Curatolo P	Tuberous sclerosis.	Lancet	2008	152
18925875	2475	García-Martínez JM	mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).	The Biochemical journal	2008	291
19234517	2475	Hartman TR	The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.	Oncogene	2009	59
19875810	2475	Lieberthal W	The role of the mammalian target of rapamycin (mTOR) in renal disease.	Journal of the American Society of Nephrology 	2009	78
20022946	2475	Soliman GA	mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.	The Journal of biological chemistry	2010	79
20368560	2475	Hainsworth JD	Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.	Journal of clinical oncology 	2010	46
20581391	2475	Serra AL	Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.	The New England journal of medicine	2010	116
20581392	2475	Walz G	Everolimus in patients with autosomal dominant polycystic kidney disease.	The New England journal of medicine	2010	125
20805416	2475	Haidinger M	A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation.	Journal of immunology	2010	57
21148113	2475	Goodman CA	Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique.	FASEB journal 	2011	90
21346035	2475	Finley DS	Tumor biology and prognostic factors in renal cell carcinoma.	The oncologist	2011	35
21511946	2475	McLean JE	Flavivirus NS4A-induced autophagy protects cells against death and enhances virus replication.	The Journal of biological chemistry	2011	57
21512002	2475	Narita M	Spatial coupling of mTOR and autophagy augments secretory phenotypes.	Science	2011	115
21606591	2475	Gödel M	Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.	The Journal of clinical investigation	2011	124
21613612	2475	Pirkmajer S	Serum starvation: caveat emptor.	American journal of physiology. Cell physiology	2011	36
21676631	2475	Liu J	Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.	Urologic oncology	2013	25
21952069	2475	Coppin C	Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.	BJU international	2011	49
22125056	2475	Weichhart T	Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life.	Methods in molecular biology	2012	34
22397650	2475	Gerlinger M	Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.	The New England journal of medicine	2012	1540
22759480	2475	Tran HT	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.	The Lancet. Oncology	2012	73
24556040	2475	Motzer RJ	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	48
24622468	2475	Voss MH	Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.	Clinical cancer research 	2014	37
24821879	2475	Brugarolas J	Molecular genetics of clear-cell renal cell carcinoma.	Journal of clinical oncology 	2014	37
25253086	2475	Jia G	Overnutrition, mTOR signaling, and cardiovascular diseases.	American journal of physiology. Regulatory, integrative and comparative physiology	2014	25
25326666	2475	Ronan B	A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.	Nature chemical biology	2014	46
26156073	2475	Bissler JJ	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.	Nephrology, dialysis, transplantation 	2016	17
26482279	2475	Motzer RJ	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.	The Lancet. Oncology	2015	57
26612197	2475	Flum AS	Update on the Diagnosis and Management of Renal Angiomyolipoma.	The Journal of urology	2016	13
26794930	2475	Armstrong AJ	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.	The Lancet. Oncology	2016	16
27134180	2475	Jiménez-Valerio G	Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.	Cell reports	2016	15
27279544	2475	Choueiri TK	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2016	35
27615548	2475	Hsieh JJ	Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.	Seminars in cell and developmental biology	2017	7
15342807	2688	Welt CK	Recombinant human leptin in women with hypothalamic amenorrhea.	The New England journal of medicine	2004	170
23418415	2688	Munch EM	Transcriptome profiling of microRNA by Next-Gen deep sequencing reveals known and novel miRNA species in the lipid fraction of human breast milk.	PloS one	2013	37
23698226	2688	Ikizler TA	Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism.	Kidney international	2013	29
11386930	2717	Schiffmann R	Enzyme replacement therapy in Fabry disease: a randomized controlled trial.	JAMA	2001	149
11439963	2717	Eng CM	Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.	The New England journal of medicine	2001	178
17179052	2717	Banikazemi M	Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.	Annals of internal medicine	2007	84
17409312	2717	Germain DP	Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.	Journal of the American Society of Nephrology 	2007	73
18940466	2717	Zarate YA	Fabry's disease.	Lancet	2008	81
17077998	2875	Flaig TW	A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.	Investigational new drugs	2007	56
18945255	2875	Loomba R	Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.	Alimentary pharmacology and therapeutics	2009	48
25873639	2875	Kwok R	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.	Gut	2016	13
15800116	3075	Appel GB	Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.	Journal of the American Society of Nephrology 	2005	72
16621965	3075	Caprioli J	Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.	Blood	2006	128
17018561	3075	Servais A	Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.	Journal of medical genetics	2007	62
17599974	3075	Sellier-Leclerc AL	Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.	Journal of the American Society of Nephrology 	2007	69
20595690	3075	Noris M	Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.	Clinical journal of the American Society of Nephrology 	2010	127
21415311	3075	Sethi S	Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.	Clinical journal of the American Society of Nephrology 	2011	36
22223606	3075	Zhang Y	Causes of alternative pathway dysregulation in dense deposit disease.	Clinical journal of the American Society of Nephrology 	2012	32
22403278	3075	Bomback AS	Eculizumab for dense deposit disease and C3 glomerulonephritis.	Clinical journal of the American Society of Nephrology 	2012	57
22456601	3075	Servais A	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.	Kidney international	2012	69
22673887	3075	Sethi S	C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.	Kidney international	2012	45
23307876	3075	Fremeaux-Bacchi V	Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.	Clinical journal of the American Society of Nephrology 	2013	72
23365078	3075	Clark SJ	Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions.	Journal of immunology	2013	34
23431077	3075	Bresin E	Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.	Journal of the American Society of Nephrology 	2013	46
24088957	3075	Sinha A	Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.	Kidney international	2014	21
25859752	3075	Loirat C	An international consensus approach to the management of atypical hemolytic uremic syndrome in children.	Pediatric nephrology	2016	24
11559532	3091	Sowter HM	HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors.	Cancer research	2001	127
12124175	3091	Mandriota SJ	HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.	Cancer cell	2002	125
12925778	3091	Metzen E	Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases.	Molecular biology of the cell	2003	86
16417408	3091	Chi JT	Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers.	PLoS medicine	2006	190
16510593	3091	Krishnamachary B	Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.	Cancer research	2006	118
17551816	3091	Semenza GL	HIF-1 mediates the Warburg effect in clear cell renal carcinoma.	Journal of bioenergetics and biomembranes	2007	78
19061835	3091	Gordan JD	HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.	Cancer cell	2008	170
21576632	3091	Xu CF	Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.	Journal of clinical oncology 	2011	39
21712410	3091	Mathieu J	HIF induces human embryonic stem cell markers in cancer cells.	Cancer research	2011	139
22055506	3091	Nandal A	Activation of the HIF prolyl hydroxylase by the iron chaperones PCBP1 and PCBP2.	Cell metabolism	2011	41
22785173	3091	Xu X	Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21.	Kidney international	2012	46
23954640	3091	Sun K	Fibrosis and adipose tissue dysfunction.	Cell metabolism	2013	90
21292778	3135	Dimopoulos M	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.	Blood	2011	62
21093036	3347	Symplicity HTN-2 Investigators.	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.	Lancet	2010	252
22573363	3347	Kandzari DE	Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.	Clinical cardiology	2012	37
23248063	3347	Esler MD	Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.	Circulation	2012	65
25400162	3347	Kandzari DE	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.	European heart journal	2015	40
15625368	3439	McDermott DF	Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2005	104
18936475	3439	Rini BI	Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.	Journal of clinical oncology 	2008	202
19171708	3439	Escudier B	Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	101
19229667	3439	Dutcher JP	Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.	Medical oncology	2009	53
19487381	3439	Motzer RJ	Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	413
20368553	3439	Escudier B	Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.	Journal of clinical oncology 	2010	152
20368558	3439	Rini BI	Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.	Journal of clinical oncology 	2010	170
24297945	3439	Rini BI	Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.	Journal of clinical oncology 	2014	29
25754160	3439	Serti E	Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.	Gastroenterology	2015	19
10438971	3458	Heeger PS	Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes.	Journal of immunology	1999	111
10479160	3458	Day NP	The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria.	The Journal of infectious diseases	1999	99
17255300	3458	Ochoa AC	Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.	Clinical cancer research 	2007	133
17379663	3458	Heidel JD	Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.	Proceedings of the National Academy of Sciences of the United States of America	2007	87
18927310	3458	Finke JH	Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.	Clinical cancer research 	2008	113
19088044	3458	Kusmartsev S	Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.	Clinical cancer research 	2008	83
19276286	3458	Ko JS	Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.	Clinical cancer research 	2009	227
19487422	3458	Strowig T	Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.	The Journal of experimental medicine	2009	92
19747917	3458	Ahlenstiel G	Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.	Gastroenterology	2010	91
23414212	3458	Sellarés J	Molecular diagnosis of antibody-mediated rejection in human kidney transplants.	American journal of transplantation 	2013	30
25244096	3458	Kirabo A	DC isoketal-modified proteins activate T cells and promote hypertension.	The Journal of clinical investigation	2014	60
26405286	3458	Getahun H	Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.	The European respiratory journal	2015	21
16600922	3479	Morley JE	Cachexia: pathophysiology and clinical relevance.	The American journal of clinical nutrition	2006	113
17617058	3479	Geraghty KM	Regulation of multisite phosphorylation and 14-3-3 binding of AS160 in response to IGF-1, EGF, PMA and AICAR.	The Biochemical journal	2007	56
18465356	3479	Frasca F	The role of insulin receptors and IGF-I receptors in cancer and other diseases.	Archives of physiology and biochemistry	2008	84
20621847	3479	Boas M	Childhood exposure to phthalates: associations with thyroid function, insulin-like growth factor I, and growth.	Environmental health perspectives	2010	48
21741057	3479	Sienkiewicz E	Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women.	Metabolism	2011	41
23388612	3490	Kashani K	Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury.	Critical care	2013	144
24067438	3490	Aregger F	Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury.	Kidney international	2014	27
24559465	3490	Bihorac A	Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication.	American journal of respiratory and critical care medicine	2014	74
24675717	3490	Meersch M	Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery.	PloS one	2014	54
25237065	3490	Hoste EA	Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers.	Nephrology, dialysis, transplantation 	2014	31
25535301	3490	Koyner JL	Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI.	Journal of the American Society of Nephrology 	2015	24
25798585	3490	Gocze I	Urinary biomarkers TIMP-2 and IGFBP7 early predict acute kidney injury after major surgery.	PloS one	2015	18
8120958	3558	Rosenberg SA	Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.	JAMA	1994	150
11357146	3558	Rosenberg SA	Progress in human tumour immunology and immunotherapy.	Nature	2001	236
12218168	3558	Wedemeyer H	Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.	Journal of immunology	2002	173
12915604	3558	Yang JC	Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.	Journal of clinical oncology 	2003	110
14974943	3558	Opelz G	Lymphomas after solid organ transplantation: a collaborative transplant study report.	American journal of transplantation 	2004	79
15632206	3558	Miller JS	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.	Blood	2005	340
15674877	3558	Coppin C	Immunotherapy for advanced renal cell cancer.	The Cochrane database of systematic reviews	2005	88
15897568	3558	Atkins M	Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.	Clinical cancer research 	2005	68
16224276	3558	Attia P	Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.	Journal of immunotherapy	2005	70
16308572	3558	Dannull J	Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.	The Journal of clinical investigation	2005	257
17093248	3558	Brennan DC	Rabbit antithymocyte globulin versus basiliximab in renal transplantation.	The New England journal of medicine	2006	77
19364969	3558	Sabatino M	Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.	Journal of clinical oncology 	2009	49
20881001	3558	Amato RJ	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.	Clinical cancer research 	2010	44
22275504	3558	Liu L	Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma.	Clinical cancer research 	2012	37
22436957	3558	Tan J	Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.	JAMA	2012	99
22674552	3558	Seung SK	Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses.	Science translational medicine	2012	56
24907378	3558	Rosenberg SA	IL-2: the first effective immunotherapy for human cancer.	Journal of immunology	2014	84
9389420	3569	Pickup JC	NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.	Diabetologia	1997	150
11445664	3569	Vozarova B	Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion.	Obesity research	2001	86
15124018	3569	Nemeth E	IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.	The Journal of clinical investigation	2004	452
15780075	3569	Stenvinkel P	IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly.	Kidney international	2005	107
15886319	3569	Kemna E	Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS.	Blood	2005	105
17716366	3569	Jeschke MG	Burn size determines the inflammatory and hypermetabolic response.	Critical care	2007	58
18235097	3569	Grigoryev DN	The local and systemic inflammatory transcriptome after acute kidney injury.	Journal of the American Society of Nephrology 	2008	70
20032961	3569	Murugan R	Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival.	Kidney international	2010	66
22421340	3569	Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium.	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.	Lancet	2012	130
23340215	3569	Singh AK	Metabolic syndrome and chronic kidney disease.	Current opinion in nephrology and hypertension	2013	27
23390498	3569	Panchapakesan U	Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?	PloS one	2013	29
24841946	3569	Lleo A	Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells.	Hepatology	2014	23
25352269	3569	Michaëlsson K	Milk intake and risk of mortality and fractures in women and men: cohort studies.	BMJ	2014	31
25388133	3569	Haake DA	Leptospirosis in humans.	Current topics in microbiology and immunology	2015	35
25787249	3569	Puthanveetil P	Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells.	Journal of cellular and molecular medicine	2015	18
26858430	3569	Morris CJ	Circadian misalignment increases cardiovascular disease risk factors in humans.	Proceedings of the National Academy of Sciences of the United States of America	2016	16
8247074	3630	Lillioja S	Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians.	The New England journal of medicine	1993	204
10550418	3630	Meyer TW	Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria.	Diabetologia	1999	104
10645822	3630	Hanson RL	Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies.	American journal of epidemiology	2000	97
11812755	3630	Vozarova B	High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes.	Diabetes	2002	84
14717908	3630	Abate N	The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance.	Kidney international	2004	74
14752837	3630	Promrat K	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.	Hepatology	2004	112
15564314	3630	Gershengorn MC	Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells.	Science	2004	100
16105055	3630	Taylor EN	Diabetes mellitus and the risk of nephrolithiasis.	Kidney international	2005	83
16250043	3630	Bugianesi E	Insulin resistance: a metabolic pathway to chronic liver disease.	Hepatology	2005	115
17065355	3630	Van den Berghe G	Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm.	Diabetes	2006	73
18347614	3630	Lawrence MC	The roles of MAPKs in disease.	Cell research	2008	54
19281826	3630	Roberts CK	Oxidative stress and metabolic syndrome.	Life sciences	2009	108
20171982	3630	Lambert GW	Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.	Pharmacology and therapeutics	2010	72
20212498	3630	Calvani R	Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype.	International journal of obesity	2010	40
21617108	3630	Sacks DB	Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.	Diabetes care	2011	65
21617152	3630	Sacks DB	Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.	Clinical chemistry	2011	56
22090277	3630	Wang T	Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance.	The Journal of clinical endocrinology and metabolism	2012	48
23413806	3630	Jones AG	The clinical utility of C-peptide measurement in the care of patients with diabetes.	Diabetic medicine 	2013	38
23594269	3630	Baudrand R	High sodium intake is associated with increased glucocorticoid production, insulin resistance and metabolic syndrome.	Clinical endocrinology	2014	22
24250251	3630	Rajendran P	The vascular endothelium and human diseases.	International journal of biological sciences	2013	62
24463448	3630	Merovci A	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.	The Journal of clinical investigation	2014	93
25035342	3630	Lim S	Links between ectopic fat and vascular disease in humans.	Arteriosclerosis, thrombosis, and vascular biology	2014	24
11781231	3791	Scharenberg CW	The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.	Blood	2002	150
18977327	3791	Würdinger T	miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells.	Cancer cell	2008	120
21882181	3791	Kim JJ	Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.	Cancer	2012	36
23139354	3791	Hodgin JB	Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli.	Diabetes	2013	39
23213094	3791	Choueiri TK	Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.	Journal of clinical oncology 	2013	72
24297950	3791	Hutson TE	Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2014	63
24827131	3791	Choueiri TK	A phase I study of cabozantinib (XL184) in patients with renal cell cancer.	Annals of oncology 	2014	22
26406150	3791	Choueiri TK	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.	The New England journal of medicine	2015	83
15711640	3934	Mori K	Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury.	The Journal of clinical investigation	2005	212
16061852	3934	Fernández CA	The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients.	Clinical cancer research 	2005	69
16528543	3934	Mishra J	Kidney NGAL is a novel early marker of acute injury following transplantation.	Pediatric nephrology	2006	73
17874137	3934	Hirsch R	NGAL is an early predictive biomarker of contrast-induced nephropathy in children.	Pediatric nephrology	2007	100
18070344	3934	Dent CL	Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study.	Critical care	2007	114
18337554	3934	Bennett M	Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study.	Clinical journal of the American Society of Nephrology 	2008	159
18379258	3934	Wheeler DS	Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock.	Critical care medicine	2008	76
18649981	3934	Wagener G	Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery.	American journal of kidney diseases 	2008	53
19148153	3934	Kuwabara T	Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons.	Kidney international	2009	64
19176795	3934	Bolignano D	Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.	Clinical journal of the American Society of Nephrology 	2009	104
19237579	3934	Yang J	Lipocalin 2 promotes breast cancer progression.	Proceedings of the National Academy of Sciences of the United States of America	2009	80
19850388	3934	Haase M	Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis.	American journal of kidney diseases 	2009	231
19956924	3934	Bagshaw SM	Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness.	Intensive care medicine	2010	87
19956925	3934	Cruz DN	Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population.	Intensive care medicine	2010	62
20056755	3934	McIlroy DR	Neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance.	Clinical journal of the American Society of Nephrology 	2010	44
20123318	3934	Aghel A	Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure.	Journal of cardiac failure	2010	54
20406069	3934	Devarajan P	Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury.	Biomarkers in medicine	2010	54
20581821	3934	Bao G	Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex.	Nature chemical biology	2010	84
20609093	3934	Devarajan P	Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury.	Nephrology	2010	66
20935115	3934	de Geus HR	Neutrophil gelatinase-associated lipocalin at ICU admission predicts for acute kidney injury in adult patients.	American journal of respiratory and critical care medicine	2011	60
21300375	3934	Krawczeski CD	Neutrophil gelatinase-associated lipocalin concentrations predict development of acute kidney injury in neonates and children after cardiopulmonary bypass.	The Journal of pediatrics	2011	42
21511111	3934	Haase M	The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies.	Journal of the American College of Cardiology	2011	133
21576334	3934	Bachman MA	Klebsiella pneumoniae yersiniabactin promotes respiratory tract infection through evasion of lipocalin 2.	Infection and immunity	2011	51
21791540	3934	Maisel AS	Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial.	European journal of heart failure	2011	41
22580944	3934	Chowdhury AH	A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte® 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers.	Annals of surgery	2012	72
23375078	3934	Singer E	Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications.	Acta physiologica	2013	28
24518531	3934	Haase-Fielitz A	Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status.	Annals of clinical biochemistry	2014	38
25311702	3934	Liu KD	Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study.	American journal of kidney diseases 	2015	18
26880194	3934	Zhang A	Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis: a systematic review and meta-analysis.	Critical care	2016	14
27209269	3934	Zarbock A	Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial.	JAMA	2016	35
2453802	4353	Falk RJ	Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.	The New England journal of medicine	1988	204
18203133	4353	Stevens JF	Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease.	Molecular nutrition and food research	2008	110
23023777	4353	Lionaki S	Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.	Arthritis and rheumatism	2012	32
19177153	4627	Freedman BI	Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.	Kidney international	2009	67
20635188	4627	Tzur S	Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.	Human genetics	2010	183
20668430	4627	Genovese G	A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9.	Kidney international	2010	55
21910715	4627	Ashley-Koch AE	MYH9 and APOL1 are both associated with sickle cell disease nephropathy.	British journal of haematology	2011	40
10430945	4758	Neumann G	Generation of influenza A viruses entirely from cloned cDNAs.	Proceedings of the National Academy of Sciences of the United States of America	1999	465
17942961	4758	Singh A	Glomerular endothelial glycocalyx constitutes a barrier to protein permeability.	Journal of the American Society of Nephrology 	2007	60
20080770	4758	Kiso M	T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.	Proceedings of the National Academy of Sciences of the United States of America	2010	50
23726392	4758	Hu Y	Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.	Lancet	2013	93
24699865	4758	Butler J	Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.	PLoS pathogens	2014	34
9660941	4868	Kestilä M	Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome.	Molecular cell	1998	383
10393930	4868	Ruotsalainen V	Nephrin is specifically located at the slit diaphragm of glomerular podocytes.	Proceedings of the National Academy of Sciences of the United States of America	1999	132
12538598	4868	Sugimoto H	Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria.	The Journal of biological chemistry	2003	98
18184729	4868	Quaggin SE	Development of the renal glomerulus: good neighbors and good fences.	Development	2008	68
22615747	4868	Jim B	Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study.	PloS one	2012	31
25635037	4868	Trautmann A	Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort.	Clinical journal of the American Society of Nephrology 	2015	27
26038526	4868	Hodgin JB	Glomerular Aging and Focal Global Glomerulosclerosis: A Podometric Perspective.	Journal of the American Society of Nephrology 	2015	28
26586691	4868	Sharmin S	Human Induced Pluripotent Stem Cell-Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation.	Journal of the American Society of Nephrology 	2016	11
18154959	4879	Daniels LB	Natriuretic peptides.	Journal of the American College of Cardiology	2007	127
2432605	5243	Fojo AT	Expression of a multidrug-resistance gene in human tumors and tissues.	Proceedings of the National Academy of Sciences of the United States of America	1987	176
2444983	5243	Thiebaut F	Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.	Proceedings of the National Academy of Sciences of the United States of America	1987	302
2563168	5243	Cordon-Cardo C	Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.	Proceedings of the National Academy of Sciences of the United States of America	1989	193
8898203	5243	van Helvoort A	MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.	Cell	1996	117
14576852	5243	Ambudkar SV	P-glycoprotein: from genomics to mechanism.	Oncogene	2003	159
8978603	5310	Qian F	The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I.	Cell	1996	110
11140688	5310	Hanaoka K	Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents.	Nature	2000	208
12482949	5310	Qian F	Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations.	Proceedings of the National Academy of Sciences of the United States of America	2002	87
16707749	5310	Grantham JJ	Volume progression in polycystic kidney disease.	The New England journal of medicine	2006	152
17090781	5310	Xu C	Human ADPKD primary cyst epithelial cells with a novel, single codon deletion in the PKD1 gene exhibit defective ciliary polycystin localization and loss of flow-induced Ca2+ signaling.	American journal of physiology. Renal physiology	2007	64
17582161	5310	Rossetti S	Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.	Journal of the American Society of Nephrology 	2007	110
19165178	5310	Rossetti S	Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.	Kidney international	2009	76
21862990	5310	Grantham JJ	Why kidneys fail in autosomal dominant polycystic kidney disease.	Nature reviews. Nephrology	2011	53
22508176	5310	Audrézet MP	Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients.	Human mutation	2012	34
23431072	5310	Cornec-Le Gall E	Type of PKD1 mutation influences renal outcome in ADPKD.	Journal of the American Society of Nephrology 	2013	62
11898128	5314	Onuchic LF	PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats.	American journal of human genetics	2002	100
12925574	5314	Ward CJ	Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia.	Human molecular genetics	2003	83
14502283	5314	Gattone VH 2nd	Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.	Nature medicine	2003	140
16319189	5314	Yamaguchi T	Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.	Journal of the American Society of Nephrology 	2006	71
12081584	5741	Chertow GM	Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.	Kidney international	2002	183
14500804	5741	Black DM	The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.	The New England journal of medicine	2003	173
14500805	5741	Finkelstein JS	The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.	The New England journal of medicine	2003	109
15176987	5741	Bekker PJ	A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.	Journal of bone and mineral research 	2004	113
15284307	5741	Block GA	Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.	Journal of the American Society of Nephrology 	2004	404
15698460	5741	Young EW	Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.	Kidney international	2005	115
15814832	5741	Slinin Y	Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.	Journal of the American Society of Nephrology 	2005	76
16316359	5741	Agarwal R	Antiproteinuric effect of oral paricalcitol in chronic kidney disease.	Kidney international	2005	84
16563471	5741	Lips P	Vitamin D physiology.	Progress in biophysics and molecular biology	2006	166
16738536	5741	Melamed ML	Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study.	Kidney international	2006	78
17091124	5741	Levin A	Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.	Kidney international	2007	242
17805238	5741	Russo D	The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.	Kidney international	2007	66
18088161	5741	Cranney A	Effectiveness and safety of vitamin D in relation to bone health.	Evidence report/technology assessment	2007	106
18299495	5741	Kovesdy CP	Association of activated vitamin D treatment and mortality in chronic kidney disease.	Archives of internal medicine	2008	60
18400938	5741	Wolf M	Impact of activated vitamin D and race on survival among hemodialysis patients.	Journal of the American Society of Nephrology 	2008	60
18463168	5741	Shoben AB	Association of oral calcitriol with improved survival in nondialyzed CKD.	Journal of the American Society of Nephrology 	2008	55
18667733	5741	Regidor DL	Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.	Journal of the American Society of Nephrology 	2008	53
19595349	5741	Fraser WD	Hyperparathyroidism.	Lancet	2009	92
19965540	5741	Oliveira RB	Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?	Clinical journal of the American Society of Nephrology 	2010	94
20593414	5741	Jüppner H	FGF-23: More than a regulator of renal phosphate handling?	Journal of bone and mineral research 	2010	44
20614473	5741	Kalantar-Zadeh K	Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients.	Journal of bone and mineral research 	2010	46
20631407	5741	Isakova T	Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.	Nephrology, dialysis, transplantation 	2011	44
20861820	5741	Wesseling-Perry K	Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.	Kidney international	2011	47
20876671	5741	Kandula P	Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials.	Clinical journal of the American Society of Nephrology 	2011	48
20947538	5741	Drechsler C	Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study.	Nephrology, dialysis, transplantation 	2011	35
21148030	5741	Raggi P	The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.	Nephrology, dialysis, transplantation 	2011	60
21159838	5741	Sai AJ	Relationship between vitamin D, parathyroid hormone, and bone health.	The Journal of clinical endocrinology and metabolism	2011	39
21183586	5741	Moe SM	Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.	Clinical journal of the American Society of Nephrology 	2011	65
21389978	5741	Isakova T	Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.	Kidney international	2011	205
21406649	5741	Palmer SC	Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.	JAMA	2011	121
21436289	5741	Wolf M	Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.	Journal of the American Society of Nephrology 	2011	65
21939825	5741	Kestenbaum B	Vitamin D, parathyroid hormone, and cardiovascular events among older adults.	Journal of the American College of Cardiology	2011	52
22052943	5741	Wesseling-Perry K	Early skeletal and biochemical alterations in pediatric chronic kidney disease.	Clinical journal of the American Society of Nephrology 	2012	33
23129826	5741	Pavik I	Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.	Nephrology, dialysis, transplantation 	2013	31
23243213	5741	Scialla JJ	Mineral metabolites and CKD progression in African Americans.	Journal of the American Society of Nephrology 	2013	28
24690624	5741	Theodoratou E	Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials.	BMJ	2014	104
10432325	5972	Sort P	Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.	The New England journal of medicine	1999	143
17161262	5972	Rossi GP	A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.	Journal of the American College of Cardiology	2006	107
18525041	5972	Parving HH	Aliskiren combined with losartan in type 2 diabetes and nephropathy.	The New England journal of medicine	2008	178
19005010	5972	Moranne O	Timing of onset of CKD-related metabolic complications.	Journal of the American Society of Nephrology 	2009	70
19289633	5972	Böger RH	Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.	Circulation	2009	61
20194303	5972	Gloviczki ML	Preserved oxygenation despite reduced blood flow in poststenotic kidneys in human atherosclerotic renal artery stenosis.	Hypertension	2010	42
20515678	5972	Tomaschitz A	Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study.	Clinica chimica acta; international journal of clinical chemistry	2010	43
22042811	5972	Marques FZ	Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs.	Hypertension	2011	37
23121378	5972	Parving HH	Cardiorenal end points in a trial of aliskiren for type 2 diabetes.	The New England journal of medicine	2012	133
23349312	5972	Savige J	Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy.	Journal of the American Society of Nephrology 	2013	28
23558162	5972	He FJ	Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials.	BMJ	2013	123
23633321	5972	He FJ	Effect of longer-term modest salt reduction on blood pressure.	The Cochrane database of systematic reviews	2013	35
24334175	5972	Cherney DZ	Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.	Circulation	2014	105
24343093	5972	Hsu TW	Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.	JAMA internal medicine	2014	28
24694989	5972	Coppo R	Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.	Kidney international	2014	35
25349246	5972	Ding Y	Autophagy in diabetic nephropathy.	The Journal of endocrinology	2015	23
25595565	5972	Goicoechea M	Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.	American journal of kidney diseases 	2015	31
19129749	6524	Komoroski B	Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.	Clinical pharmacology and therapeutics	2009	60
19357717	6524	Bakris GL	Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.	Kidney international	2009	47
20546255	6524	Gerich JE	Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.	Diabetic medicine 	2010	67
21672123	6524	Strojek K	Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.	Diabetes, obesity and metabolism	2011	73
22310849	6524	Ferrannini E	SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.	Nature reviews. Endocrinology	2012	41
23735727	6524	DeFronzo RA	Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.	Diabetes care	2013	32
24067431	6524	Kohan DE	Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.	Kidney international	2014	68
24631482	6524	Oliva RV	Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.	Journal of the American Society of Hypertension 	2014	33
24673844	6524	De Nicola L	Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.	American journal of kidney diseases 	2014	23
24918789	6524	Usiskin K	Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.	Postgraduate medicine	2014	27
25246775	6524	Nauck MA	Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.	Drug design, development and therapy	2014	32
25341005	6524	Vallon V	The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.	Annual review of medicine	2015	18
25488697	6524	Scheen AJ	Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.	Drugs	2015	22
26078479	6524	Peters AL	Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.	Diabetes care	2015	48
26086329	6524	Taylor SI	SGLT2 Inhibitors May Predispose to Ketoacidosis.	The Journal of clinical endocrinology and metabolism	2015	43
26604280	6524	Mudaliar S	Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.	Diabetes care	2015	18
26861783	6524	Ferrannini E	Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.	Diabetes	2016	15
27470878	6524	Heerspink HJ	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.	Circulation	2016	17
28120497	6524	Neal B	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.	Diabetes, obesity and metabolism	2017	6
8702570	7018	Keith DE	Morphine activates opioid receptors without causing their rapid internalization.	The Journal of biological chemistry	1996	125
9186882	7018	Hunsicker LG	Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study.	Kidney international	1997	116
20201089	7018	Lu M	FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.	American journal of hematology	2010	81
22327295	7018	Noinaj N	Structural basis for iron piracy by pathogenic Neisseria.	Nature	2012	57
25060056	7018	Lewis JB	Ferric citrate controls phosphorus and delivers iron in patients on dialysis.	Journal of the American Society of Nephrology 	2015	24
15231748	7040	Colland F	Functional proteomics mapping of a human signaling pathway.	Genome research	2004	79
16408108	7040	Liu Y	Renal fibrosis: new insights into the pathogenesis and therapeutics.	Kidney international	2006	235
17500590	7040	Samols MA	Identification of cellular genes targeted by KSHV-encoded microRNAs.	PLoS pathogens	2007	137
20971881	7040	Cushing L	miR-29 is a major regulator of genes associated with pulmonary fibrosis.	American journal of respiratory cell and molecular biology	2011	139
21368745	7040	Trachtman H	A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.	Kidney international	2011	59
21866313	7040	van Meeteren LA	Regulation of endothelial cell plasticity by TGF-β.	Cell and tissue research	2012	54
22335797	7040	Vallon V	Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney.	Annual review of physiology	2012	46
24618589	7040	Morris JC	Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.	PloS one	2014	41
26335400	7040	Richter K	Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences.	Redox biology	2015	18
20686651	7369	Gudbjartsson DF	Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases.	PLoS genetics	2010	42
12520530	7421	Holick MF	Vitamin D: A millenium perspective.	Journal of cellular biochemistry	2003	196
16946007	7421	Norman AW	Minireview: vitamin D receptor: new assignments for an already busy receptor.	Endocrinology	2006	102
18606901	7421	Alborzi P	Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial.	Hypertension	2008	90
18689389	7421	Norman AW	From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health.	The American journal of clinical nutrition	2008	114
1791831	7422	Houck KA	The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.	Molecular endocrinology	1991	199
8167412	7422	Park JE	The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.	Molecular biology of the cell	1993	181
12124351	7422	Bates DO	VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.	Cancer research	2002	143
12890841	7422	Yang JC	A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.	The New England journal of medicine	2003	446
15149314	7422	Schrijvers BF	The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.	Kidney international	2004	90
15611513	7422	Kim WY	Role of VHL gene mutation in human cancer.	Journal of clinical oncology 	2004	209
16330672	7422	Motzer RJ	Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2006	245
17158546	7422	Motzer RJ	Targeted therapy for metastatic renal cell carcinoma.	Journal of clinical oncology 	2006	64
17261421	7422	Zhu X	Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.	American journal of kidney diseases 	2007	124
17475821	7422	Lindenmeyer MT	Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy.	Journal of the American Society of Nephrology 	2007	69
18156031	7422	Escudier B	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.	Lancet	2007	433
19129259	7422	Satchell SC	Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier.	American journal of physiology. Renal physiology	2009	51
19224847	7422	Feldman DR	Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	70
19451442	7422	Escudier B	Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.	Journal of clinical oncology 	2009	216
19581909	7422	Chen HX	Adverse effects of anticancer agents that target the VEGF pathway.	Nature reviews. Clinical oncology	2009	90
20156114	7422	Ranpura V	Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.	Acta oncologica	2010	43
20501804	7422	Hammers HJ	Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.	Molecular cancer therapeutics	2010	49
21074201	7422	Choueiri TK	The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.	The Journal of urology	2011	48
21527770	7422	Rini BI	Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.	Journal of the National Cancer Institute	2011	115
21752957	7422	Woroniecka KI	Transcriptome analysis of human diabetic kidney disease.	Diabetes	2011	93
22056247	7422	Rini BI	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.	Lancet	2011	303
22608783	7422	Lambrechts D	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.	The Lancet. Oncology	2012	44
23312463	7422	Heng DY	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.	The Lancet. Oncology	2013	71
24135488	7422	Buczek M	Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.	Biochimica et biophysica acta	2014	24
24841777	7422	Albiges L	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.	European urology	2015	22
25452452	7422	Motzer RJ	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.	Journal of clinical oncology 	2015	120
7915601	7428	Gnarra JR	Mutations of the VHL tumour suppressor gene in renal carcinoma.	Nature genetics	1994	298
7937876	7428	Herman JG	Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	1994	236
8493574	7428	Latif F	Identification of the von Hippel-Lindau disease tumor suppressor gene.	Science	1993	389
11238039	7428	Ivanov S	Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.	The American journal of pathology	2001	128
14985465	7428	Zimmer M	Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.	Molecular cancer research 	2004	80
16488999	7428	Banks RE	Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.	Cancer research	2006	73
16585181	7428	Esteban MA	Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.	Cancer research	2006	80
17450132	7428	Thoma CR	pVHL and GSK3beta are components of a primary cilium-maintenance signalling network.	Nature cell biology	2007	67
18676741	7428	Nickerson ML	Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.	Clinical cancer research 	2008	133
20651059	7428	Peña C	Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.	Clinical cancer research 	2010	49
21725364	7428	Niu X	The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.	Oncogene	2012	46
25952651	7428	Wettersten HI	Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.	Cancer research	2015	22
8395349	7490	Kreidberg JA	WT-1 is required for early kidney development.	Cell	1993	299
10101119	7490	Moore AW	YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis.	Development	1999	102
15365188	7490	Oka Y	Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.	Proceedings of the National Academy of Sciences of the United States of America	2004	100
17361230	7490	Yang L	A tumor suppressor and oncogene: the WT1 story.	Leukemia	2007	96
11737582	8074	White KE	Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.	Kidney international	2001	111
14633152	8074	Larsson T	Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.	Kidney international	2003	147
15284207	8074	Bai X	Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders.	Endocrinology	2004	73
15613425	8074	Ferrari SL	Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.	The Journal of clinical endocrinology and metabolism	2005	99
15917335	8074	Gutierrez O	Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.	Journal of the American Society of Nephrology 	2005	195
16735491	8074	Antoniucci DM	Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.	The Journal of clinical endocrinology and metabolism	2006	103
17063170	8074	Nishida Y	Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men.	Kidney international	2006	60
17656479	8074	Fliser D	Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.	Journal of the American Society of Nephrology 	2007	169
17699549	8074	Perwad F	Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro.	American journal of physiology. Renal physiology	2007	66
18282132	8074	Wang H	Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro.	Journal of bone and mineral research 	2008	52
18687639	8074	Gutiérrez OM	Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.	The New England journal of medicine	2008	368
19181315	8074	Mirza MA	Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community.	Atherosclerosis	2009	90
19395730	8074	Jean G	High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.	Nephrology, dialysis, transplantation 	2009	73
19414634	8074	Gutiérrez OM	Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.	Circulation	2009	185
19524924	8074	Mirza MA	Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.	Atherosclerosis	2009	85
19844248	8074	Razzaque MS	The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis.	Nature reviews. Endocrinology	2009	81
20176609	8074	Nasrallah MM	Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients.	Nephrology, dialysis, transplantation 	2010	43
20507943	8074	Wolf M	Forging forward with 10 burning questions on FGF23 in kidney disease.	Journal of the American Society of Nephrology 	2010	67
20525642	8074	Seiler S	FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.	Nephrology, dialysis, transplantation 	2010	47
20613714	8074	Yilmaz MI	FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease.	Kidney international	2010	41
20966399	8074	Mirza MA	Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals.	Arteriosclerosis, thrombosis, and vascular biology	2011	39
21030580	8074	Vervloet MG	Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.	Clinical journal of the American Society of Nephrology 	2011	43
21454719	8074	Cunningham J	Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.	Clinical journal of the American Society of Nephrology 	2011	51
21673295	8074	Isakova T	Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.	JAMA	2011	213
21903574	8074	Kendrick J	FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.	Journal of the American Society of Nephrology 	2011	120
22034506	8074	Gutiérrez OM	Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study.	Clinical journal of the American Society of Nephrology 	2011	36
22109743	8074	Desjardins L	FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages.	Osteoporosis international 	2012	50
22492635	8074	Lim K	Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.	Circulation	2012	99
22622492	8074	Wolf M	Update on fibroblast growth factor 23 in chronic kidney disease.	Kidney international	2012	59
22703926	8074	Ix JH	Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).	Journal of the American College of Cardiology	2012	82
22886720	8074	Bacchetta J	Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.	Journal of bone and mineral research 	2013	30
22951890	8074	Ärnlöv J	Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community.	Kidney international	2013	36
23187128	8074	Smith RC	Circulating αKlotho influences phosphate handling by controlling FGF23 production.	The Journal of clinical investigation	2012	32
23389416	8074	Scialla JJ	Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.	Kidney international	2013	54
23505057	8074	Wolf M	Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.	Journal of bone and mineral research 	2013	44
24158986	8074	Scialla JJ	Fibroblast growth factor-23 and cardiovascular events in CKD.	Journal of the American Society of Nephrology 	2014	63
24686452	8074	Scialla JJ	Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.	Nature reviews. Nephrology	2014	25
25967123	8074	Isakova T	Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.	Journal of the American Society of Nephrology 	2015	17
26059012	8074	Moe SM	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.	Circulation	2015	23
21997392	8542	Madhavan SM	APOL1 localization in normal kidney and nondiabetic kidney disease.	Journal of the American Society of Nephrology 	2011	70
22135313	8542	Fine DM	APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease.	Journal of the American Society of Nephrology 	2012	33
22357707	8542	Tzur S	APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease.	Nephrology, dialysis, transplantation 	2012	33
22832513	8542	Lipkowitz MS	Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.	Kidney international	2013	66
23438974	8542	Genovese G	APOL1 variants and kidney disease in people of recent African ancestry.	Nature reviews. Nephrology	2013	28
23520206	8542	Larsen CP	Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy.	Journal of the American Society of Nephrology 	2013	33
23766536	8542	Foster MC	APOL1 variants associate with increased risk of CKD among African Americans.	Journal of the American Society of Nephrology 	2013	57
23768513	8542	Ko WY	Identifying Darwinian selection acting on different human APOL1 variants among diverse African populations.	American journal of human genetics	2013	28
24206458	8542	Parsa A	APOL1 risk variants, race, and progression of chronic kidney disease.	The New England journal of medicine	2013	149
24231663	8542	Bruggeman LA	Plasma apolipoprotein L1 levels do not correlate with CKD.	Journal of the American Society of Nephrology 	2014	23
24379297	8542	Ito K	Increased burden of cardiovascular disease in carriers of APOL1 genetic variants.	Circulation research	2014	52
24504811	8542	Freedman BI	End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.	Arthritis and rheumatology	2014	47
24899058	8542	Lan X	APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.	American journal of physiology. Renal physiology	2014	32
24903390	8542	Freedman BI	Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.	Clinical journal of the American Society of Nephrology 	2014	23
25029429	8542	Langefeld CD	Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial.	Kidney international	2015	29
26634651	8542	Mukamal KJ	APOL1 Genotype, Kidney and Cardiovascular Disease, and Death in Older Adults.	Arteriosclerosis, thrombosis, and vascular biology	2016	14
26699492	8542	Olabisi OA	APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.	Proceedings of the National Academy of Sciences of the United States of America	2016	12
15615823	9771	Poggio ED	Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease.	Journal of the American Society of Nephrology 	2005	96
20299365	9771	Michels WM	Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size.	Clinical journal of the American Society of Nephrology 	2010	52
20430946	9771	Meijers BK	p-Cresol and cardiovascular risk in mild-to-moderate kidney disease.	Clinical journal of the American Society of Nephrology 	2010	48
16613591	10133	Meier-Kriesche HU	Immunosuppression: evolution in practice and trends, 1994-2004.	American journal of transplantation 	2006	66
23237695	10133	Matas AJ	OPTN/SRTR 2011 Annual Data Report: kidney.	American journal of transplantation 	2013	39
24373166	10133	Matas AJ	OPTN/SRTR 2012 Annual Data Report: kidney.	American journal of transplantation 	2014	67
12527804	10242	Nelson ME	Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors.	Molecular pharmacology	2003	162
16183856	10242	Kuryatov A	Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors.	Molecular pharmacology	2005	108
16720757	10242	Moroni M	alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine.	Molecular pharmacology	2006	101
18381563	10242	Kuryatov A	Roles of accessory subunits in alpha4beta2(*) nicotinic receptors.	Molecular pharmacology	2008	84
19262355	10242	Labarga P	Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.	AIDS	2009	56
17005808	10257	Ray AS	Mechanism of active renal tubular efflux of tenofovir.	Antimicrobial agents and chemotherapy	2006	74
17978814	10257	Huls M	The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.	Kidney international	2008	51
19400747	10257	Rodríguez-Nóvoa S	Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.	Clinical infectious diseases 	2009	51
21103974	10257	Keppler D	Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy.	Handbook of experimental pharmacology	2011	51
18650507	10599	SEARCH Collaborative Group.	SLCO1B1 variants and statin-induced myopathy--a genomewide study.	The New England journal of medicine	2008	353
10390358	10686	Simon DB	Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption.	Science	1999	178
25540137	10686	de Baaij JH	Magnesium in man: implications for health and disease.	Physiological reviews	2015	46
17267747	10724	Liangos O	Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure.	Journal of the American Society of Nephrology 	2007	107
18059454	10724	Han WK	Urinary biomarkers in the early diagnosis of acute kidney injury.	Kidney international	2008	106
18519927	10724	Nickolas TL	Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury.	Annals of internal medicine	2008	157
19212447	10724	Vaidya VS	Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans.	Clinical and translational science	2008	91
19406962	10724	Han WK	Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery.	Clinical journal of the American Society of Nephrology 	2009	81
20072112	10724	Phisitkul S	Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR.	Kidney international	2010	48
20164825	10724	Morales AI	Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway.	Kidney international	2010	48
20659949	10724	Damman K	Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate.	Heart	2010	45
18682239	10736	Kobayashi A	Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development.	Cell stem cell	2008	232
18835385	10736	Mugford JW	Osr1 expression demarcates a multi-potent population of intermediate mesoderm that undergoes progressive restriction to an Osr1-dependent nephron progenitor compartment within the mammalian kidney.	Developmental biology	2008	85
21350016	10736	Karner CM	Canonical Wnt9b signaling balances progenitor cell expansion and differentiation during kidney development.	Development	2011	74
22902740	10736	Park JS	Six2 and Wnt regulate self-renewal and commitment of nephron progenitors through shared gene regulatory networks.	Developmental cell	2012	66
23996934	10736	Harari-Steinberg O	Identification of human nephron progenitors capable of generation of kidney structures and functional repair of chronic renal disease.	EMBO molecular medicine	2013	31
24429398	10736	Hwang DY	Mutations in 12 known dominant disease-causing genes clarify many congenital anomalies of the kidney and urinary tract.	Kidney international	2014	30
25358792	10736	Kobayashi A	Identification of a multipotent self-renewing stromal progenitor population during mammalian kidney organogenesis.	Stem cell reports	2014	25
26458176	10736	Morizane R	Nephron organoids derived from human pluripotent stem cells model kidney development and injury.	Nature biotechnology	2015	31
19571279	22925	Beck LH Jr	M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.	The New England journal of medicine	2009	284
22673885	22925	Hoxha E	Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.	Kidney international	2012	44
23223223	22925	Svobodova B	Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy.	Nephrology, dialysis, transplantation 	2013	41
23364522	22925	Kanigicherla D	Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.	Kidney international	2013	47
23637987	22925	Oh YJ	Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy.	PloS one	2013	28
23813219	22925	Lv J	Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy.	Journal of the American Society of Nephrology 	2013	28
25205735	22925	Kao L	Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy.	Journal of the American Society of Nephrology 	2015	21
15707414	23523	Brennan DC	Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction.	American journal of transplantation 	2005	83
19118301	23523	Moers C	Machine perfusion or cold storage in deceased-donor kidney transplantation.	The New England journal of medicine	2009	81
21070604	23523	Lo DJ	Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.	American journal of transplantation 	2011	49
21334736	23523	Budde K	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.	Lancet	2011	43
23349326	23523	Reinders ME	Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study.	Stem cells translational medicine	2013	66
26604182	23523	Sawinski D	Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents.	American journal of transplantation 	2016	14
9461608	26762	Ichimura T	Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury.	The Journal of biological chemistry	1998	236
17471468	26762	van Timmeren MM	Tubular kidney injury molecule-1 (KIM-1) in human renal disease.	The Journal of pathology	2007	100
19387469	26762	Vaidya VS	A rapid urine test for early detection of kidney injury.	Kidney international	2009	54
19572801	26762	Liangos O	Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass.	Biomarkers 	2009	56
19762491	26762	Hall IE	IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation.	Journal of the American Society of Nephrology 	2010	81
20980978	26762	Vaidya VS	Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase.	Kidney international	2011	54
22034509	26762	Hall IE	Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis.	Clinical journal of the American Society of Nephrology 	2011	37
23348975	26762	Takasu O	Mechanisms of cardiac and renal dysfunction in patients dying of sepsis.	American journal of respiratory and critical care medicine	2013	67
24357673	26762	Coca SG	Urinary biomarkers of AKI and mortality 3 years after cardiac surgery.	Journal of the American Society of Nephrology 	2014	28
24404151	26762	Shao X	Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis.	PloS one	2014	24
15569934	29126	Thompson RH	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.	Proceedings of the National Academy of Sciences of the United States of America	2004	181
16482562	29126	Blank C	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.	International journal of cancer	2006	75
16585157	29126	Thompson RH	Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.	Cancer research	2006	198
17186290	29126	Nakanishi J	Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.	Cancer immunology, immunotherapy 	2007	65
17340590	29126	Inman BA	PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.	Cancer	2007	63
25193987	29126	Choueiri TK	PD-L1 expression in nonclear-cell renal cell carcinoma.	Annals of oncology 	2014	42
25424850	29126	McDermott DF	The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.	Clinical cancer research 	2015	19
25538263	29126	Choueiri TK	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.	Clinical cancer research 	2015	27
25695955	29126	Patel SP	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.	Molecular cancer therapeutics	2015	104
25856776	29126	Homet Moreno B	Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.	British journal of cancer	2015	34
26895815	29126	Gandini S	PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.	Critical reviews in oncology/hematology	2016	27
27267608	29126	Goldberg SB	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.	The Lancet. Oncology	2016	29
27269937	29126	Massard C	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.	Journal of clinical oncology 	2016	31
28131785	29126	Sharma P	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.	The Lancet. Oncology	2017	16
12697741	54474	Eghbali-Fatourechi G	Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.	The Journal of clinical investigation	2003	141
12853585	54474	Sarwal M	Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.	The New England journal of medicine	2003	138
17709552	54474	Ahuja A	Depletion of B cells in murine lupus: efficacy and resistance.	Journal of immunology	2007	79
20501946	54474	Newell KA	Identification of a B cell signature associated with renal transplant tolerance in humans.	The Journal of clinical investigation	2010	160
11113131	57817	Park CH	Hepcidin, a urinary antimicrobial peptide synthesized in the liver.	The Journal of biological chemistry	2001	329
15671438	57817	Papanikolaou G	Hepcidin in iron overload disorders.	Blood	2005	92
18166790	57817	Kemna EH	Hepcidin: from discovery to differential diagnosis.	Haematologica	2008	51
18628991	57817	Swinkels DW	Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry.	PloS one	2008	52
18689548	57817	Ganz T	Immunoassay for human serum hepcidin.	Blood	2008	151
21989113	57817	Kroot JJ	Hepcidin in human iron disorders: diagnostic implications.	Clinical chemistry	2011	36
22290531	57817	Sun CC	Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.	American journal of hematology	2012	37
22306005	57817	Ganz T	Hepcidin and iron homeostasis.	Biochimica et biophysica acta	2012	145
26314490	57817	Lopez A	Iron deficiency anaemia.	Lancet	2016	19
16696865	90678	Hoste EA	RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis.	Critical care	2006	264
16715038	90678	Uchino S	An assessment of the RIFLE criteria for acute renal failure in hospitalized patients.	Critical care medicine	2006	156
17396113	90678	Akcan-Arikan A	Modified RIFLE criteria in critically ill children with acute kidney injury.	Kidney international	2007	160
17962378	90678	Bagshaw SM	A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients.	Nephrology, dialysis, transplantation 	2008	93
18160961	90678	Ricci Z	The RIFLE criteria and mortality in acute kidney injury: A systematic review.	Kidney international	2008	153
19349297	90678	Bagshaw SM	A comparison of observed versus estimated baseline creatinine for determination of RIFLE class in patients with acute kidney injury.	Nephrology, dialysis, transplantation 	2009	51
19438394	90678	Hartzell JD	Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.	Clinical infectious diseases 	2009	64
20124891	90678	Schneider J	Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit.	Critical care medicine	2010	45
21232094	90678	Englberger L	Clinical accuracy of RIFLE and Acute Kidney Injury Network (AKIN) criteria for acute kidney injury in patients undergoing cardiac surgery.	Critical care	2011	44
12024214	116085	Enomoto A	Molecular identification of a renal urate anion exchanger that regulates blood urate levels.	Nature	2002	176
18701466	116085	Anzai N	Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.	The Journal of biological chemistry	2008	60
16807400	146802	Masuda S	Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2.	Journal of the American Society of Nephrology 	2006	67
17509534	146802	Tanihara Y	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.	Biochemical pharmacology	2007	70
23267855	146802	Stocker SL	The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.	Clinical pharmacology and therapeutics	2013	28
12194920	201163	Katzmann JA	Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.	Clinical chemistry	2002	86
15852235	201163	Schmidt LS	Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome.	American journal of human genetics	2005	80
18403135	201163	Hasumi H	Identification and characterization of a novel folliculin-interacting protein FNIP2.	Gene	2008	58
19959076	201163	Menko FH	Birt-Hogg-Dubé syndrome: diagnosis and management.	The Lancet. Oncology	2009	67
22977732	201163	Nookala RK	Crystal structure of folliculin reveals a hidDENN function in genetically inherited renal cancer.	Open biology	2012	31
